Figure 1
From: Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693
Treatment with GSK690693 leads to inhibited phosphorylation of kinase targets of AKT. Inhibition of AKT kinase activity is evidenced by decreased phosphorylation of kinase targets of the protein, including PRAS40 (AKT1S1), mTOR (FRAP1), FKHR/FKHRL1 (FOXO1A/FOXO3A), BAD and GSK3a/b in BT474, MDA-MB-453, MDA-MB-468, and T47D breast cancer cell lines, mean +/- S.D. Bar graphs: blue: control, red: treated with GSK690693; y-axis: relative intensity units.